Severity
Critical
FDA Drug recall · Reported May 27, 2026
Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
Wisconsin Pharmacal Company recalled MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz… - a critical-severity action.
MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz… was recalled by Wisconsin Pharmacal Company in May 27, 2026. Reason: Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.. Check the official notice for the remedy. Verify recall #D-0553-2026 with the FDA Drug before acting.
The recall
Wisconsin Pharmacal Company issued this critical-severity FDA Drug recall-Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus..
Sourced from official FDA Drug enforcement records. Verify recall #D-0553-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0553-2026) was formally reported on May 27, 2026, with the manufacturer initiating the action on April 24, 2026. It is classified under Critical severity (Class I), with a current status of Ongoing. Wisconsin Pharmacal Company is listed as the recalling firm, operating out of Jackson, WI. Federal records list the affected scope as 690 tubes.
The documented reason for this recall is: Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus. Distribution data in the federal record shows the product reached: USA Nationwide and Bahamas. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 3 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 1,360 cosmetics & personal care recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
690 tubes
Related Recalls
6
3 from same agency
MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g), Manufactured by: Pharmacal 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037.
Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Ongoing |
| Recall number | D-0553-2026 |
| Date reported | May 27, 2026 |
| Date initiated | April 24, 2026 |
| Recalling firm | Wisconsin Pharmacal Company |
| Firm location | Jackson, WI |
| Affected scope | 690 tubes |
| Distribution | USA Nationwide and Bahamas |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-06-04
PS Seasoning & Spices, Inc. · 2026-05-27
Fontana Flavors, Inc · 2026-05-27
SUN PHARMACEUTICAL INDUSTRIES INC · 2026-04-22
Owen Biosciences Inc. · 2026-04-22
Compare this recall with Tiny Land Children's Play Tents Recalled Due to Risk of Inj… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 27, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.